No Data
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $75
Aligos Therapeutics Q3 2024 GAAP EPS $(3.07) Misses $(2.15) Estimate, Sales $1.269M Beat $333.333K Estimate
Express News | Aligos Therapeutics Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing
Express News | Aligos Therapeutics Inc - Cash Balance Provides Sufficient Cash to Fund Planned Operations Through End of 2025
Aligos Therapeutics | 10-Q: Q3 2024 Earnings Report
Aligos Therapeutics 3Q Loss/Shr $3.07 >ALGS
No Data
No Data